Intracellular localization of CK2α as a prognostic factor in invasive breast carcinomas

Invasive ductal carcinoma (IDC) is the most common histopathological type of breast cancer, accounting for up to 85% of all invasive breast carcinomas [1]. It spreads usually to the bone first. Solitary metastasis is commonly located in the lung, liver or brain [2]. Adrenal glands locations are extremely rare [3]. We report a case of isolated metachronous right adrenal metastasis, diagnosed four years after breast IDC management. The aim is to highlight clinical, diagnostic and therapeutic characteristics of this entity.

Download Full-text

Ultrasound-Guided Laser-Induced Thermal Therapy for Small Palpable Invasive Breast Carcinomas: A Feasibility Study

Annals of Surgical Oncology ◽

10.1245/s10434-009-0544-z ◽

2009 ◽

Vol 16 (8) ◽

Cited By ~ 53

Author(s):

S. van Esser ◽

G. Stapper ◽

P. J. van Diest ◽

M. A. A. J. van den Bosch ◽

J. H. G. M. Klaessens ◽

...

Keyword(s):

Feasibility Study ◽

Thermal Therapy ◽

Breast Carcinomas ◽

Ultrasound Guided ◽

Invasive Breast Carcinomas

Download Full-text

Evaluation of Biomarkers in Multiple Ipsilateral Synchronous Invasive Breast Carcinomas

Archives of Pathology & Laboratory Medicine ◽

10.5858/arpa.2017-0494-oa ◽

2018 ◽

Vol 143 (2) ◽

pp. 190-196

Author(s):

Pooja Navale ◽

Ira J. Bleiweiss ◽

Shabnam Jaffer ◽

Anupma Nayak

Keyword(s):

New York ◽

Progesterone Receptor ◽

Mount Sinai Hospital ◽

Breast Carcinomas ◽

Tumor Focus ◽

Biomarker Testing ◽

Major Variation ◽

Index Tumor ◽

Invasive Breast Carcinomas ◽

Additional Tumor

Context.— The College of American Pathologists guidelines recommend testing additional tumor foci in multifocal invasive breast carcinomas for the biomarkers estrogen receptor (ER), progesterone receptor, and HER2 only if the carcinomas show different morphologies or grades. Objective.— To assess clinical significance of testing for biomarkers in additional tumor foci in multifocal invasive breast tumors. Design.— Retrospective analysis of 118 patients diagnosed with ipsilateral synchronous multifocal breast carcinomas from January 2015 through March 2016 at Mount Sinai Hospital (New York, New York). Results.— Eighty-six cases were tested for at least 1 of the 3 biomarkers in additional tumor foci. Fifteen cases (17%) showed discordant staining between the 2 foci for at least one biomarker. Of the 7 of 67 ER-discordant cases (10%), 4 (57%) showed major variation from negative to positive expression, including 3 cases in which a smaller tumor focus was strongly positive for ER whereas the index tumor was negative. Similarly, within the 7 of 67 progesterone receptor–discordant cases (10%), 4 (57%) showed major variation from negative to positive, and in 3 cases with major discordance, the index tumor was negative for progesterone receptor, whereas a smaller focus was positive. A difference in HER2 expression was noted in 5 of 86 cases (6%). In only 5 of the 15 patients (33%) with discordant results, biomarker testing on additional foci would have been offered per the College of American Pathologists recommendations because of differences in histology or grading. Of the remaining 10 patients, 7 (70%) with positive results on smaller foci would have been deprived of appropriate adjuvant systemic treatment if the smaller focus had not been tested. Conclusions.— We propose that negative values expressed in the primary tumor be repeated routinely on additional ipsilateral synchronous tumors.

Download Full-text